OptiNose (OPTN) Stock Price

OptiNose Price

NASDAQ·CLOSED
9.60
​
Market closed

Revenue has compounded at 113.5% per year over the past 9 years to 78.23 M USD. OptiNose's net margin stands at -27.5%, up from -200.2% several years earlier. Analysts set a median price target of 9.18 USD, implying 4.4% below the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.

OptiNose stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose business model & stock analysis

OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists.

Frequently asked questions about OptiNose

Analysts currently set an average price target of 9.18 USD for the OptiNose stock (median: 9.18 USD), implying -4.4 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the OptiNose stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect OptiNose to generate revenue of 113.60 M USD and earnings per share of -0.84 USD.

Converted at the current exchange rate, the OptiNose share trades at 8.58 EUR (9.60 USD).

The OptiNose share (OPTN) is listed on 3 stock exchanges, including: NASDAQ (OPTN), Frankfurt (0OP.F), München (0OP.MU).

The expected revenue of OptiNose is 113.60 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of OptiNose is -9.83 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of OptiNose is currently -11.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OptiNose stock.

The price-to-sales ratio (P/S) of OptiNose is currently 0.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OptiNose stock.

The Eulerpool Quality Score for OptiNose is 3/10.

The ISIN of OptiNose is US68404V2097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OptiNose is A2H5PR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OptiNose is OPTN. The ticker symbol is used to trade OptiNose shares on the stock exchange.

Fair ValueTerminal
8.83 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
615,952.76 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Oct 13, 2017
ISIN
US68404V2097
Cusip
68404V100
Sedol
BYZ2JT0
Market capitalization
97.25 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-4.86
P/Ee 2026
-11.37
P/Ee 2027
42.67
P/Ee 2028
-52.51
P/Ee 2029
9.50
P/S
P/Se
1.12
EV/EBIT
—
P/B Ratio
14.33
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-25.01 %
Last updated Nov 11, 2026, 4:43 PM

OptiNose Ticker

FRANKFURT · 0OP.FMUNICH · 0OP.MUNASDAQ · OPTN

All fundamentals and in-depth analysis of OptiNose

Our stock analysis for OptiNose stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OptiNose. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.